Evonik extends efficiency drive with deeper job cuts, shares in focus on MDAX
22.06.2026 - 18:14:33 | ad-hoc-news.de
By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-22, 18:10.
Evonik (DE000EVNK013) is pushing its efficiency agenda further with a deeper round of restructuring. The MDAX-listed specialty chemicals group plans to cut around 3,200 jobs worldwide under its "Tailor Made" program, with implementation stretching to the end of 2029, according to recent reports citing company statements and local media.
What Evonik is changing now
The extended program, often referred to as "Evonik Customized" or "Tailor Made", will touch all global business lines and functional units and aims at structural cost savings beyond the targets set in 2023, when Evonik initially announced around 2,800 job cuts by 2026. The updated plan now foresees roughly 3,200 positions being reduced worldwide, of which about 2,150 are located in Germany, according to a June 22 summary of company comments reported by Golden Ten Data and Chinese outlet Jiemian.
Evonik confirmed to Jiemian that around 1,050 roles are to be eliminated outside Germany, including in the China region, though the company has not yet specified the exact number of Chinese positions to be affected. Management has stated earlier in 2024 that the efficiency drive is intended to support profitability in a challenging chemicals environment and free up resources for growth areas, as reflected in prior comments on the progress of the program in May. As a specialty chemicals peer of BASF and Covestro, Evonik continues to re-balance its portfolio between classic bulk businesses and higher-margin solutions.
Sector view and analyst focus
Evonik shares trade in Frankfurt and on Xetra and are part of the MDAX as well as the Stoxx Europe 600 chemicals cohort, where restructuring stories remain a central investment theme. Sector investors compare Evonik with peers such as BASF and LANXESS when assessing cost-cutting measures, capital discipline and exposure to cyclical end-markets like construction, automotive and consumer goods. Third-party analysis on platforms following Evonik’s ADR in the United States highlights the focus on margin improvement and portfolio streamlining as key levers for value creation over the medium term.
Recent market commentary on the ADR side points to muted trading activity but reiterates that structural cost savings and a stronger focus on specialty segments could support earnings quality once the current chemicals downcycle stabilizes. For European mid-cap benchmarks such as the MDAX and the Stoxx Europe 600, operational restructuring and disciplined capital allocation remain recurring themes in analyst discussions of industrial and chemicals names.
All news and analysis on the Evonik shares
Further background, regulatory disclosures and historical reports on Evonik are collected in the topic overview and in the company's own investor-relations section.
How Evonik earns its money
Evonik generates most of its revenue in specialty chemicals, including additives, polymers and performance materials used in consumer goods, automotive, construction and life-science applications. One representative product line is its high-performance additives for coatings and adhesives, which help customers improve durability, processing and efficiency in industrial applications. The group also serves nutrition, healthcare and advanced materials markets with tailored solutions that typically carry higher margins than basic commodity chemicals.
Where the Evonik shares trade today
Evonik shares (DE000EVNK013) most recently changed hands on Xetra at 15.93 euros on 2026-06-22, 13:34, according to intraday data from Frankfurt.
Evonik at a glance
- Company: Evonik Industries AG
- ISIN: DE000EVNK013
- WKN: EVNK01
- Ticker: EVK
- Trading venue: Xetra
- Price (as of 2026-06-22, 13:34): 15.93 EUR
- Market cap: around 7.4 billion EUR (as of 2026-06-22)
- Sector / industry: Specialty chemicals / industrials
- Index membership: MDAX, Stoxx Europe 600
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or any other form of financial guidance. Investors should conduct their own research or consult a licensed financial advisor before making investment decisions.
